D. McDonald

Phase 1/2a, open‐label, multicenter study of RM‐1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma

M. Biel, A. Gillenwater, K. Stenson, 2021, Head & neck.

Results of a phase 2a, multicenter, open-label, study of RM-1929 photoimmunotherapy (PIT) in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).

M. Biel, A. Gillenwater, K. Stenson, 2019, Journal of Clinical Oncology.

RM-1929 photo-immunotherapy in patients with recurrent head and neck cancer: Results of a multicenter phase 2a open-label clinical trial.

A. Gillenwater, K. Stenson, M. Razaq, 2018 .

1051PDA phase 1, multicenter, open-label, dose-escalation, combination study of RM-1929 and photoimmunotherapy in patients with recurrent head and neck cancer

K. Stenson, M. Razaq, M. Fidler, 2017 .